APRE Aprea Therapeutics

Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com

Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
EN
14/10/2020

Underlying

APREAprea Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aprea Therapeutics

Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
FATE FATE THERAPEUTICS INC
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
2303 UNITED MICROELECTRONICS CORP.
ROKU ROKU INC. CLASS A
TSEM TOWER SEMICONDUCTOR LTD
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
RZLT REZOLUTE
IMNM IMMUNOME
TNGX TANGO THERAPEUTICS
GFS INC
TYRA GLOBALFOUNDRIES INC
NUVL TYRA BIOSCIENCES INC
BCAX NUVALENT INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
10/27/25 October 27, 2025 1 EN
David Nierengarten ... (+6)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
XNCR XENCOR INC.
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
TNGX TANGO THERAPEUTICS
TYRA INC
NUVL TYRA BIOSCIENCES INC
BCAX NUVALENT INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
10/27/25 October 27, 2025 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Sho...

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors harboring mutations relevant to WEE1 kinase inhibition (FBXW7, CCNE1, KRAS G12V and TP53)Dose escalation continues, with patients now enrolling in 150 mg cohortPreliminary results from ACESOT-1051 trial through September 17, 2025 to be feature...

October 24, 2025 1 EN
Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
TSLA TESLA INC
TPH TRI POINTE HOMES INC.
PEGA PEGASYSTEMS INC.
MELI MERCADOLIBRE INC.
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
10/23/25 October 23, 2025 1 EN
David Nierengarten ... (+6)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
XNCR XENCOR INC.
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
10/23/25 October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch